CalcMyPeptide
Khavinson BioregulatorAlso known as: Bronchial Extract Bioregulator, Bronchial Cytomax

Taxorest

Taxorest is a profoundly potent Cytomax natural peptide bioregulator, composed of highly targeted extractions from young bronchial mucosa. Regarded as the natural, full-spectrum biological twin to Bronchogen, it is a key component to aggressive respiratory restoration. Clinically favored for violently halting age-related chronic bronchitis, rapidly repairing airway damage from prolonged smoking, and drastically clearing deeply entrenched alveolar mucus.

Reviewed by CalcMyPeptide Editorial Team
Last updated: April 2026Evidence: Low1 peer-reviewed citation

Quick Stats

Half-LifeMixture (variable)
Dose Range1-2 capsules/day
Frequency1-2× daily for 10-30 day cycles
Vial SizesN/A (oral)
BioavailabilityOral capsules
Year Developed1980s

Scientific Data

Molecular Formula
Polypeptide extract (Bronchial tissue <10 kDa)
Molecular Weight
Mixture (<10 kDa)
PubChem ID

Mechanism of Action

Taxorest (A-19) is a Cytomax natural polypeptide extract from the bronchial mucosa of young calves, targeting human bronchial epithelial cells, Clara cells, and type II pneumocytes to restore age-silenced gene expression governing mucociliary clearance, surfactant synthesis, and bronchial anti-inflammatory signaling. The lungs undergo progressive structural aging: mucociliary clearance slows (reducing the ability to expel inhaled particles), alveolar surface area declines by 4 m² per decade after age 30, and type II pneumocyte reserve capacity for surfactant production diminishes, contributing to declining FEV1 and increased respiratory infection susceptibility.

Taxorest delivers short peptide signals (<10 kDa) from bovine bronchial tissue. These peptides penetrate bronchial cell nuclei to reactivate transcription of genes encoding: CFTR (cystic fibrosis transmembrane conductance regulator, critical for airway surface liquid homeostasis), MUC5AC and MUC5B (airway mucins essential for the gel-on-brush mucociliary defense system), surfactant protein D (SP-D, which neutralizes inhaled pathogens), and IL-10 (bronchial anti-inflammatory cytokine). This is a tissue restoration mechanism — not a bronchodilator or anti-inflammatory drug.

In Khavinson's protocols, Taxorest (A-19, bronchial) is often paired with Chelohart (A-14, heart) and Ventfort (A-3, blood vessels) for the cardiovascular-pulmonary system bundle, since pulmonary vascular resistance and gas exchange efficiency are directly coupled to cardiac output demands.

Source: PMID: 15677927

Background & History

Taxorest is the bronchial Cytomax extract — natural counterpart to synthetic Bronchogen.

Research Use Cases

  • Respiratory health
  • COPD support
  • Bronchial function

Dosing Protocol

Typical Dose1-2 capsules/day
Frequency1-2× daily for 10-30 day cycles
Half-Life~30 minutes (estimated)

Dosing Protocols

Mini-Course / General Preventive (1 box)

Dose
2 capsules (20 mg)
Frequency
Once daily for 10 days, 30 min before meals
Note: Standard Khavinson mini-course (20 caps). Repeat every 6 months. For smokers or those with occupational exposure, combine with Chelohart (A-14) for the pulmonary-cardiac support bundle.

Full Monthly Course (COPD / Chronic Lung Support)

Dose
2 capsules (20 mg)
Frequency
Twice daily for 30 days (120 caps = 2× 60-cap boxes)
Note: Bi-annual 30-day courses for adults with COPD stage I–II, chronic bronchitis, post-COVID lung recovery, or significant smoking history. Core pulmonary stack: Taxorest (A-19) + Chelohart (A-14) + Ventfort (A-3).

Intensive / Pulmonary Restoration Protocol

Dose
2 capsules (20 mg)
Frequency
Twice daily, repeated monthly
Note: Post-COVID long-haul respiratory recovery, active COPD management support (adjunct), or occupational dust/chemical exposure. Physician supervision required. Not a bronchodilator or replacement for inhaled therapy. Max: 4 caps/day (40 mg).

Administration

Route
Oral capsules (20-cap and 60-cap boxes)
Timing
30 minutes before meals. Morning + evening for intensive courses.
Fasting Required?
Yes — inject on an empty stomach

Expected Timeline

Days 1—14
Bronchial epithelial gene expression restoration initiated. Early improvement in mucociliary clearance capacity.
Month 1–2
Reduced chronic cough frequency, improved bronchial secretion consistency, better morning respiratory quality.
Month 3–6
Sustained improvement in bronchial mucosal integrity. Reduced respiratory infection frequency.

Who Is It For?

Respiratory Aging / COPD Support

Low

Targets bronchial epithelial and Clara cell gene expression. Restores mucociliary clearance and surfactant production at the transcription level.

Post-COVID Lung Recovery

Low

Used in Russian longevity protocols for post-viral airway mucosal rehabilitation. Addresses the bronchial epithelial damage component of long COVID respiratory symptoms.

Safety & Considerations

Natural glandular extract (Cytomax) from bovine bronchial tissue, <10 kDa. No hormones. Meets European/Russian veterinary standards. Generally recognized as safe.

Regulatory & Legal Status

FDA Status (US)
Research Only
WADA Status (2026)
Not Listed

Not currently on the WADA 2026 Prohibited List. Policies may change — verify before competition.

Classification

Research Chemical

US Compounding: Not eligible / not available

⚠️ This information is for educational purposes only and may not reflect the most current regulatory updates. Always verify with official FDA, WADA, and jurisdiction-specific sources before use.

Interactions & Contraindications

Standard Cytomax capsule protocol.

Synergies & Common Stacks

Taxorest (Cytomax) + Bronchogen (synthetic) = layered respiratory support.

Dosing Quick Reference

Taxorest— Dosing Guide
Dose Range
1-2 capsules/day
Half-Life
~30 minutes (estimated)
Frequency
1-2× daily for 10-30 day cycles
Route
Oral
Khavinson Bioregulatorcalcmypeptide.com

Frequently Asked Questions

Is Taxorest a bronchodilator?
No. Taxorest does not dilate bronchial smooth muscle or affect airway resistance acutely. It works by restoring the gene expression of the bronchial epithelium — improving mucociliary clearance capacity, surfactant production, and bronchial anti-inflammatory signaling over the course of weeks to months.
Can Taxorest help after COVID-19?
Post-COVID respiratory symptoms often involve persistent bronchial epithelial dysfunction and reduced mucociliary clearance. Taxorest addresses these at the cellular gene expression level. It is used in Russian longevity medicine alongside Endoluten (A-8, immunity/circadian) and Vladonix (A-6, thymus) for post-viral recovery protocols.

References

  1. Khavinson VKh "Peptide bioregulators — a new class of geroprotectors".” Bulletin of Experimental Biology and Medicine (2002). PMID: 12677266

📚 Related Articles

Recommended SourceOral Bioregulator

Get Taxorest from Vita-Stream — the comprehensive distributor for authentic Khavinson bioregulators. Oral capsules, no injections required.

Affiliate link · Full review